Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and mk-0524

rosiglitazone has been researched along with mk-0524 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Greenblatt, DJ1
Gao, B; Lai, E; Liu, F; Meehan, AJ; Rosko, K; Ruckle, J; Schwartz, JI; Stroh, M; Wagner, JA; Zajic, S1

Trials

1 trial(s) available for rosiglitazone and mk-0524

ArticleYear
Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone.
    Cardiovascular therapeutics, 2009,Winter, Volume: 27, Issue:4

    Topics: Adult; Cross-Over Studies; Drug Interactions; Female; Humans; Hypoglycemic Agents; Indoles; Middle Aged; Receptors, Immunologic; Receptors, Prostaglandin; Rosiglitazone; Thiazolidinediones

2009

Other Studies

1 other study(ies) available for rosiglitazone and mk-0524

ArticleYear
Drug-drug noninteractions.
    Cardiovascular therapeutics, 2009,Winter, Volume: 27, Issue:4

    Topics: Data Interpretation, Statistical; Drug Interactions; Humans; Hypoglycemic Agents; Indoles; Receptors, Immunologic; Receptors, Prostaglandin; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration

2009